Regeneron Pharmaceuticals Inc (NASDAQ:REGN)
| 685.47 Delayed Data As of Sep 26 |  -11.86 / -1.70%Today’s Change | 538.01 Today|||52-Week Range 754.67 | +8.54% Year-to-Date |
Latest REGN News | Press Releases
| Should Goldman Sachs Equal Weight U.S. Large Cap Equity ETF (GSEW) Be on Your Investing Radar? Sep 26 / Zacks.com - Paid Partner Content | 2 Biotech Stocks You Can Buy and Hold for the Next Decade Sep 19 / MotleyFool.com - Paid Partner Content |
| AstraZeneca's (AZN) Asthma Drug Tezepelumab Gets Nod in Europe Sep 22 / Zacks.com - Paid Partner Content | Regeneron (REGN)/ Alnylam Report Promising Data from NASH Study Sep 16 / Zacks.com - Paid Partner Content |
| Roche's (RHHBY) Vabysmo Gets Approval for nAMD & DME in Europe Sep 19 / Zacks.com - Paid Partner Content | Adverum (ADVM) Doses First Patient in the Mid-Stage wAMD Study Sep 15 / Zacks.com - Paid Partner Content |
| Intellia (NTLA) Reports Positive Results for CRISPR Candidates Sep 19 / Zacks.com - Paid Partner Content | Biotech Stock Roundup: BMY Surges on Drug Approval, REGN Up on Update & More Sep 14 / Zacks.com - Paid Partner Content |
Today’s Trading
| Previous close | 697.33 |
| Today’s open | 695.93 |
| Day’s range | 682.71 - 696.09 |
| Volume | 39,016 |
| Average volume (3 months) | 703,635 |
| Market cap | $76.0B |
Data as of 4:01pm ET, 09/26/2022
Growth & Valuation
| Earnings growth (last year) | +133.99% |
| Earnings growth (this year) | -43.90% |
| Earnings growth (next 5 years) | +1.50% |
| Revenue growth (last year) | +89.14% |
| P/E ratio | 13.7 |
| Price/Sales | 4.41 |
| Price/Book | 4.04 |
Competitors
Data as of 4:01pm ET, 09/26/2022
Financials
| Next reporting date | November 8, 2022 |
| EPS forecast (this quarter) | $9.85 |
| Annual revenue (last year) | $16.1B |
| Annual profit (last year) | $8.1B |
| Net profit margin | 50.25% |
Profile
Sector Health Technology |
Industry Pharmaceuticals: Major |
No executives to display |
Corporate headquarters Tarrytown, New York |
Forecasts
